Human Medicines Symposium 2017

A wide range of speakers from the MHRA, other European national agencies, the EMA, the European Commission, plus industry will provide a broad range of insight and discussion into the world of regulatory affairs on matters affecting us today and in the future. Discuss and understand proposed regulations and the wider issues affecting your regulatory role.

Programme

  Monday, 2 October
12.40

TOPRA Annual Lecture 2017

Dr Murray M. Lumpkin, Deputy Director, Integrated Development (Regulatory Affairs), Lead for Global Regulatory Systems Initiatives, Global Health | Integrated Development, USA.


13.15–14.45

Session 1: Delivering the European Network Strategy – progress to date

Two years into the joint HMA/EMA (Heads of Medicines Agencies/European Medicines Agency) high-level Strategy to 2020, plans were developed and priorities identified. What progress has been made so far? And where are new priorities emerging?

Leader:

Speakers:

  • to be confirmed

14.45 Break
15.15–16.45

Session 2: Ensuring timely regulatory approval of medicines and access for patients

Following the global push to accelerate regulatory review, increase stakeholder involvement and optimise evidence-based drug development, this session considers initiatives that expedite the approval process and improve access to medicines.

Leader:

Speakers:

  • to be confirmed

16.45 Tea break
17.15–18.45

Session 3: Regulatory collaborations on the world stage

The EMA, US FDA and Japanese PMDA are working together to deliver better regulatory processes and healthcare – and the impact of the Bill & Melinda Gates Foundation work.

Leader:

Speakers confirmed:


18.45 Symposium networking dinner

Programme subject to change.

Please email us if you'd like a copy of the full programme.

No content found

No content found

No content found